Folger Nolan Fleming Douglas Capital Management Inc. Increases Stock Holdings in Johnson & Johnson $JNJ

Folger Nolan Fleming Douglas Capital Management Inc. lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 104,039 shares of the company’s stock after buying an additional 3,864 shares during the period. Johnson & Johnson makes up 2.3% of Folger Nolan Fleming Douglas Capital Management Inc.’s portfolio, making the stock its 10th biggest position. Folger Nolan Fleming Douglas Capital Management Inc.’s holdings in Johnson & Johnson were worth $25,431,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of JNJ. Sierra Capital LLC grew its stake in shares of Johnson & Johnson by 0.5% in the fourth quarter. Sierra Capital LLC now owns 8,144 shares of the company’s stock worth $1,685,000 after acquiring an additional 41 shares during the period. Beaird Harris Wealth Management LLC lifted its position in Johnson & Johnson by 1.8% during the fourth quarter. Beaird Harris Wealth Management LLC now owns 2,422 shares of the company’s stock valued at $501,000 after purchasing an additional 42 shares during the period. Broadleaf Partners LLC boosted its holdings in Johnson & Johnson by 0.6% in the fourth quarter. Broadleaf Partners LLC now owns 7,348 shares of the company’s stock worth $1,521,000 after purchasing an additional 43 shares during the last quarter. Jessup Wealth Management Inc boosted its holdings in Johnson & Johnson by 0.6% in the fourth quarter. Jessup Wealth Management Inc now owns 7,574 shares of the company’s stock worth $1,567,000 after purchasing an additional 44 shares during the last quarter. Finally, Plancorp LLC grew its position in Johnson & Johnson by 0.3% in the 4th quarter. Plancorp LLC now owns 15,889 shares of the company’s stock worth $3,288,000 after purchasing an additional 45 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Insider Activity at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of Johnson & Johnson stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the transaction, the executive vice president directly owned 114,288 shares of the company’s stock, valued at $27,560,551.20. The trade was a 8.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Daiwa Securities Group increased their price target on Johnson & Johnson from $237.00 to $246.00 and gave the company an “outperform” rating in a report on Thursday, April 16th. Johnson Rice set a $270.00 price objective on Johnson & Johnson in a report on Friday, June 26th. JPMorgan Chase & Co. upped their price objective on Johnson & Johnson from $250.00 to $260.00 and gave the company a “neutral” rating in a research report on Wednesday, April 15th. Morgan Stanley set a $283.00 target price on Johnson & Johnson in a report on Wednesday, April 15th. Finally, Sanford C. Bernstein boosted their price target on Johnson & Johnson from $225.00 to $251.00 and gave the company a “market perform” rating in a research note on Wednesday, April 15th. Twenty analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $256.70.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson launched its Dual-Energy THERMOCOOL SMARTTOUCH SF cardiac ablation catheter platform in Europe, expanding access for electrophysiologists and adding another potential growth driver for its med-tech business. Johnson & Johnson (JNJ) Launches Dual-Energy Cardiac Ablation Catheter in Europe
• Positive Sentiment: The company is drawing attention as a top dividend and defensive healthcare name, with articles highlighting its reliable payout, global healthcare reach, and appeal to income-focused investors. Is It Worth Investing in Johnson & Johnson (JNJ) Based on Wall Street’s Bullish Views?
• Positive Sentiment: Johnson & Johnson is being favored for long-term growth because management is emphasizing cancer and neuroscience, while expanding its oncology pipeline through regulatory progress in Europe and the planned Firefly Bio acquisition. Johnson & Johnson (JNJ) Expands Cancer Pipeline As Talc Verdict Eases One Risk
• Neutral Sentiment: Several articles compare J&J with other dividend and healthcare stocks or discuss passive-income strategies, but these are more general investor-interest pieces than direct company-specific catalysts. 3 Dividend Stocks to Buy Hand Over Fist in July
• Neutral Sentiment: Analysts are watching J&J’s Q2 Innovative Medicine business closely, with Stelara biosimilar pressure potentially offset by growth from newer drugs and blockbusters ahead of earnings. J&J’s Innovative Medicine Business in Q2: Here’s What to Watch
• Negative Sentiment: One near-term risk remains biosimilar competition for Stelara, which could weigh on Innovative Medicine growth if newer products do not fully offset the pressure. J&J’s Innovative Medicine Business in Q2: Here’s What to Watch

Johnson & Johnson Trading Up 3.4%

Shares of Johnson & Johnson stock opened at $262.52 on Friday. Johnson & Johnson has a 1-year low of $154.21 and a 1-year high of $263.10. The company’s fifty day simple moving average is $232.98 and its 200-day simple moving average is $231.04. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77. The stock has a market capitalization of $631.93 billion, a PE ratio of 30.35, a P/E/G ratio of 2.49 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.68 by $0.02. The firm had revenue of $24.06 billion during the quarter, compared to analyst estimates of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.Johnson & Johnson’s revenue was up 9.9% on a year-over-year basis. During the same period in the prior year, the business posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, equities analysts anticipate that Johnson & Johnson will post 11.57 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th were paid a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend was Tuesday, May 26th. Johnson & Johnson’s dividend payout ratio is 61.97%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.